The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma. - Wikidata - wikimedia - TriplyDB

The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma.

The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma.

http://www.wikidata.org/entity/Q40220487

about

Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges Genetic Polymorphisms of CCL22 and CCR4 in Patients with Lung Cancer.Fully human antagonistic antibodies against CCR4 potently inhibit cell signaling and chemotaxis.CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells Immune cell recruitment and cell-based system for cancer therapy.Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells.Detrimental role of CC chemokine receptor 4 in murine polymicrobial sepsis.Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity.Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314.Humanized tumor mice--a new model to study and manipulate the immune response in advanced cancer therapy.Antibody therapy for Adult T-cell leukemia-lymphoma.A case of post-mogamulizumab relapse of acute-type adult T-cell leukemia/lymphoma successfully treated with mogamulizumab and etoposide.Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia/lymphoma using G-CSF.No effect of humanized CCR monoclonal antibody (mogamulizumab) on treatment-resistant adult T cell leukemia with meningeal infiltration.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.

P2860

Q26866236-79C5681B-064C-41A0-9201-4A5704B3F64E Q33907317-D8B9017F-0DC8-4D86-9017-A5D4CF21F246 Q33982582-939BE91B-05CB-4B91-86AD-FE02D9CCD51A Q36288217-CD999361-6F81-4DD0-ADDF-E7F86264BE50 Q36392832-7C24EAB1-C93F-4F9B-9B94-82646E0045F7 Q36517706-CB6A8F72-9E55-4A6F-9E97-4BF7139B7543 Q36617341-AD640621-10A5-43FE-86E8-2226F37CD549 Q36949926-9590106D-C274-48D7-B00B-738CC7F4A4B0 Q38286374-B8D2F5E8-CF99-4C8C-9C0F-793ADA83EA65 Q38982777-657378B8-0791-4C42-AEB8-174D50C48803 Q39337108-A9B8FA6A-62A2-4DFA-8041-30B10D2AB596 Q39547654-9298A479-1563-4849-8639-2B432237D158 Q39698098-08FEE67D-B47E-41E5-B1BB-FDB42977E9BB Q42141309-381E9EB0-24DE-42DB-A3C8-CB10B4443B4B Q43078116-8E49705C-64E2-49C1-97AD-B4D27C840B55 Q44391545-ABE6CD4D-D9C9-4CF6-A350-4E9F81CCB9D8 Q49539698-134F91A6-B9A5-4B8B-B131-E2D3A52E09E8

P2860

The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma.

http://www.wikidata.org/entity/Q40220487

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma.

@en

type

label

The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma.

@en

prefLabel

The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma.

@en

P1433

Q40220487-A1241630-F3EB-4DE2-A3E7-E6DE968D571C

P1476

Q40220487-A5B67725-473E-4CA1-8E68-0C185EB76676

P2093

Q40220487-0E2F7186-34A2-4C1B-B8B9-7D64730A4D0D

Q40220487-1CF79806-0E82-4968-8151-B4149382519F

Q40220487-52398219-034B-4A7B-9ECF-8424D0F0B101

Q40220487-5DFF2550-4EA0-491B-8FA5-B51D43DA59BD

Q40220487-71F11C6F-F0E1-4EBB-9EED-4D81C416FD02

Q40220487-9DBB67BD-61D5-4036-B2FC-BA6D7C698283

Q40220487-F0BB59C4-D297-4F4F-B030-4FC744761644

Q40220487-F87E295A-7DF6-4935-BBA2-78511F5FB340

Q40220487-FC17F8F1-C7D6-4E1C-8394-17DEFD02B4B1

P2860

Q40220487-06E16711-01DD-40A9-9AEB-A05E4669862C

Q40220487-081F9A65-C822-45EB-AA74-F7150638A394

Q40220487-08E43C6E-56B7-4224-BBB4-3C12B23C74F4

Q40220487-27EF3496-A37F-4AD7-946D-A5D631ECDEEC

Q40220487-4F957C2B-D85F-4B17-8FFD-5D9D5D5C9744

Q40220487-5930664E-1FD2-46A5-ABE3-2FEE5076C8DB

Q40220487-6D3C7EC6-755D-443A-B554-D4889B04EE53

Q40220487-7864C2D5-20B8-41CD-98E9-65A75E2951DC

Q40220487-828C121B-16C4-414A-8883-90E4EFB05B5A

Q40220487-9278E3CF-C5B4-45CC-BDE9-FE4479FFE100

P2888

Q40220487-A36C9C9C-1063-4F4B-9A65-CF1F3DAE6650

P304

Q40220487-64087EEE-4550-497D-AD84-317968A4115E

P31

Q40220487-DAC2BBDB-EF62-4BD3-BF6C-176EDA459674

P356

Q40220487-4D31653F-94F9-4CCF-9140-A095D76CE972

P433

Q40220487-E07E17C2-2635-41D3-B458-A3DFF31FBCDC

P478

Q40220487-79F3EE67-B41F-4642-A3A1-6A2187AA2469

P50

Q40220487-D1D509EB-74CA-4073-93A6-1F8AC7DED8AD

P577

Q40220487-CEEC58C0-FCC6-4820-A3FD-66F3C1D80D85

P5875

Q40220487-497BE306-6F16-485C-9057-59B04C623D52

P6179

Q40220487-9FEA1BA7-ED63-450E-BEA3-C7381050C55E

P698

Q40220487-5C47A1C7-B99E-42C6-BFE9-63BE650B4D00

P921

Q40220487-BBCA2181-46E9-4C2E-A4CF-5F67832CE38E

P356

P1433

P1476

The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma.

@en

P2093

Iida S

http://www.w3.org/2001/XMLSchema#string

Inagaki A

http://www.w3.org/2001/XMLSchema#string

Inagaki H

http://www.w3.org/2001/XMLSchema#string

Ishii T

http://www.w3.org/2001/XMLSchema#string

Komatsu H

http://www.w3.org/2001/XMLSchema#string

Kusumoto S

http://www.w3.org/2001/XMLSchema#string

Ri M

http://www.w3.org/2001/XMLSchema#string

Ueda R

http://www.w3.org/2001/XMLSchema#string

Yano H

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells.

Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays.

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density.

Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.

P2888

P304

2162-2168

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.LEU.2404415

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6756673

http://www.w3.org/2001/XMLSchema#string

P6179

1017583112

http://www.w3.org/2001/XMLSchema#string

P698

17039235

http://www.w3.org/2001/XMLSchema#string

P921